Onco-Innovations Ltd. ( (TSE:ONCO) ) just unveiled an update.
Onco-Innovations Limited announced that its subsidiary, Inka Health, has filed a provisional patent application for its AI-powered precision medicine platform, SynoGraph, with the USPTO. This platform aims to enhance precision medicine by using AI-driven causal inference to identify cancer patients likely to respond to specific treatments, potentially optimizing treatment decisions and clinical trial designs. The patent filing is a strategic move to protect the company’s proprietary technology, strengthen its position in the healthcare technology sector, and open opportunities for collaborations and commercialization.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company specializing in oncology, dedicated to cancer research and treatment. The company focuses on preventing and curing cancer through pioneering research and innovative solutions, with a mission to improve patient outcomes and set new standards in cancer treatment. Onco-Innovations has secured an exclusive worldwide license to patented technology targeting solid tumors.
YTD Price Performance: 203.53%
Average Trading Volume: 420,504
See more data about ONCO stock on TipRanks’ Stock Analysis page.